Resultados globales: 2 registros encontrados en 0.01 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
10 p, 577.6 KB Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension / Mantegazza, Renato (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Wolfe, Gil I. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Muppidi, Srikanth (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Wiendl, Heinz (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Fujita, Kenji P. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; O'Brien, Fanny L. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Booth, Heather D.E. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Howard, James F (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau) ; Cortés-Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Rojas-Garcia, Ricard (Institut d'Investigació Biomèdica Sant Pau) ; Vidal-Fernández, Núria (Institut d'Investigació Biomèdica Sant Pau)
OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. [...]
2021 - 10.1212/WNL.0000000000011207
Neurology, Vol. 96 Núm. 4 (january 2021) , p. e610-e618  
2.
11 p, 286.2 KB Long-term safety and efficacy of eculizumab in generalized myasthenia gravis / Muppidi, Srikanth (Stanford University School of Medicine) ; Utsugisawa, Kimiaki (Hanamaki General Hospital) ; Benatar, Michael (University of Miami Miller School of Medicine) ; Murai, Hiroyuki (International University of Health and Welfare) ; Barohn, Richard J. (University of Kansas Medical Center) ; Illa, Isabel (Hospital Universitari Vall d'Hebron) ; Jacob, Saiju (Birmingham Women's and Children's Hospital (Regne Unit)) ; Vissing, John (University of Copenhagen) ; Burns, Ted M. (University of Virginia Health System) ; Kissel, John T. (The Ohio State University) ; Nowak, Richard J. (Yale University) ; Andersen, Henning (Aarhus University Hospital (Aarhus, Dinamarca)) ; Casasnovas, Carlos (Hospital Universitari de Bellvitge) ; De Bleecker, Jan (Universitair Ziekenhuis Gent) ; Vu, Tuan H. (University of South Florida) ; Mantegazza, Renato (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; O'Brien, Fanny L. (Alexion Pharmaceuticals) ; Wang, Jing Jing (Alexion Pharmaceuticals) ; Fujita, Kenji P (Alexion Pharmaceuticals) ; Howard, James F. (University of North Carolina)
Introduction : Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. [...]
2019 - 10.1002/mus.26447
Muscle & nerve, Vol. 60 (march 2019) , p. 14-24  

Vea también: autores con nombres similares
2 Fujita, K.
1 Fujita, K.P.
1 Fujita, Kazutoshi
1 Fujita, Kenji P
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.